Skip to main content
Prestige Biologics Co., Ltd. logo

Prestige Biologics Co., Ltd. — Investor Relations & Filings

Ticker · 334970 ISIN · KR7334970001 KO Manufacturing
Open in API
Filings indexed 203 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 334970

About Prestige Biologics Co., Ltd.

https://prestigebiologics.com/en/

Prestige Biologics is a biopharmaceutical Contract Development and Engineering Manufacturing Organization (CDEMO) that provides end-to-end solutions for the entire lifecycle of a drug, from initial development to commercial production. The company specializes in antibody-based therapeutics and offers a comprehensive suite of services including process development, analytical testing, manufacturing of drug substances and drug products, and secondary packaging for clinical trials. It supports clients through all clinical stages by providing services optimized for their specific needs, utilizing advanced equipment and GMP-compliant facilities.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 92% confidence The document is a fully detailed Korean “분기보고서” (quarterly report) covering the third quarter of the 12th fiscal year (2025-07-01 to 2026-03-31). It includes a full set of financial statements, notes, management discussion and analysis, auditor opinions, corporate overview, business review, segment data, and other substantive financial and operational disclosures. This matches the criteria for an Interim/Quarterly Report (IR). Q3 2026
2026-05-15 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 90% confidence The document is a Korean stock exchange disclosure announcing the conclusion of a single sales and supply contract (“단일판매ㆍ공급계약체결”) by Prestige BioLogics. It provides contract terms, amounts and periods but does not present full financial statements or constitute a financial report. It is a regulatory announcement of a material contract rather than an interim report, capital raise, or governance filing. As there is no dedicated category for contract awards, it falls into the fallback “Regulatory Filings” category.
2026-05-15 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a disclosure about a single sales and supply contract agreement, including details about contract amount, counterparties, contract period, and payment terms. It also includes a correction notice related to the contract and mentions confidentiality and continuous disclosure withholding due to the counterparty's request. The document is short (1790 characters) and primarily serves as a regulatory announcement of a contract agreement and its correction, not a financial report or detailed analysis. There is no financial statement or management discussion. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2026-04-30 Korean
단일판매ㆍ공급계약해지
Regulatory Filings Classification · 95% confidence The document is a short announcement about the termination of a single sales and supply contract, including details such as contract amount, counterpart, contract period, and reasons for termination. It does not contain financial statements or detailed financial analysis. The length is only 1063 characters, indicating it is a brief regulatory announcement rather than a full report. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a contract termination and does not match other more specific categories like Annual Report, Earnings Release, or Capital Update.
2026-04-30 Korean
단기차입금증가결정
Capital/Financing Update Classification · 91% confidence The document is a formal announcement detailing the decision to increase short-term borrowings (단기차입금 증가결정), including amounts, purpose, and board resolution details. This clearly describes a financing activity (debt financing update). Therefore, it fits the “Capital/Financing Update” category.
2026-04-23 Korean
자산재평가결과(자율공시)
Regulatory Filings Classification · 80% confidence The document is a voluntary regulatory disclosure (자율공시) detailing the results of an asset revaluation (토지 재평가결과) including revaluation amounts, accounting entries, and related notes. It is not an annual or interim report, earnings release, proxy statement, dividend notice, or share issuance document. It is a standalone regulatory announcement of a specific accounting event with no dedicated category, so it falls under the general “Regulatory Filings” fallback.
2026-04-02 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.